Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMERI.L Regulatory News (MERI)

  • There is currently no data for MERI

Portfolio Update

29 Jul 2020 07:00

RNS Number : 3883U
Merian Chrysalis Investment Co. Ltd
29 July 2020
 

For immediate release

 

The information contained in this announcement is restricted and is not for publication, release or distribution in the United States of America, any member state of the European Economic Area (other than professional investors in the Republic of Ireland), Canada, Australia, Japan or the Republic of South Africa.

 

Merian Chrysalis Investment Company Limited

29 July 2020

 

Merian Chrysalis Investment Company Limited (the "Company")

 

Portfolio Update

 

The Company today confirms that the underlying asset referred to in the announcement dated 20 July 2020 is TransferWise Ltd ("TransferWise"), where it has participated in TransferWise's US$319 million secondary share sale, which valued the business at US$5 billion.

The transaction is the first sale conducted by the Company and has generated a significant return for shareholders. The share price implied by this transaction represents a gross uplift on the Company's initial investment price in November 2018 of 2.2x, or 1.7x on an average price basis. The latter implies an internal rate of return of circa 63% (on a US dollar basis, assuming the new valuation is applied to the remaining TransferWise holding in the Company).

As of the Interim Report to 31 March 2020, TransferWise comprised over 18% of the Company's NAV, and this transaction represented an opportunity to control the size of the Company's position at this new valuation; the Investment Advisor continues to believe in the long-term investment case for TransferWise.

This disposal has increased the Company's available cash balance by circa £20 million to approximately £55 million. The Investment Advisor intends to use the proceeds raised to reinvest in the portfolio and continues to assess a range of new ideas and follow-on opportunities.

Nick Williamson, portfolio manager, comments:

"TransferWise has been a very successful investment for Merian Chrysalis, having delivered a gross valuation uplift of approximately $50m over our holding period. It still represents a significant part of our portfolio and we continue to be excited by growth prospects for the business. Its new valuation demonstrates the attractiveness to global investors of tech-enabled disruptors as they scale up, and we're delighted to be able to crystallise some of this gain for the benefit of our shareholders."

Richard Watts, portfolio manager, adds:

"The sale represents a significant moment for Merian Chrysalis. In the Interim Report we expressed our aspirations to move into the Company's second phase, the "growth" phase, with an eye on phase three - "realisations" - in due course. This transaction has allowed us to deliver on both of these goals: it has driven NAV progression, and also demonstrated our ability to recycle capital to fund future investments in the portfolio."

ENDS

For further information, please contact:

Merian Global Investors:

Amelie Shepherd

+44 (0) 20 3817 1686

 

Liberum:

Gillian Martin / Owen Matthews

+44 (0) 20 3100 2000

 

Maitland Administration (Guernsey) Limited:

Elaine Smeja

+44 (0) 1481 749364

 

LEI: 213800F9SQ753JQHSW24

A copy of this announcement will be available on the Company's website at https://www.merian.com/chrysalis/. Neither the content of the Company's website, nor the content on any website accessible from hyperlinks on its website for any other website, is incorporated into, or forms part of, this announcement nor, unless previously published by means of a recognised information service, should any such content be relied upon in reaching a decision as to whether or not to acquire, continue to hold, or dispose of, securities in the Company.

This announcement may include "forward-looking statements". All statements other than statements of historical facts included in this announcement, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's products and services) are forward-looking statements.

Forward-looking statements are subject to risks and uncertainties and accordingly the Company's actual future financial results and operational performance may differ materially from the results and performance expressed in, or implied by, the statements. These factors include but are not limited to those described in the formal Prospectus. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Services and Markets Act 2000, the Listing Rules or Prospectus Regulation Rules of the Financial Conduct Authority or other applicable laws, regulations or rules.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PFUFZGZNVRKGGZM
12
Date   Source Headline
19th Mar 202012:09 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
18th Mar 20202:51 pmRNSDirector/PDMR Shareholding
13th Mar 20207:00 amRNSNet Asset Value(s)
9th Mar 20204:36 pmRNSPrice Monitoring Extension
28th Feb 20204:05 pmRNSResult of AGM
17th Feb 20203:11 pmRNSCorporate Update
30th Jan 20207:00 amRNSNotice of AGM
24th Jan 20207:00 amRNSFinal Results
15th Jan 20203:46 pmRNSAppointment of Senior Independent Director
15th Jan 20207:00 amRNSPortfolio Update
11th Dec 20197:00 amRNSPortfolio Update
3rd Dec 20197:00 amRNSNet Asset Value(s)
27th Nov 20197:00 amRNSPortfolio Update
23rd Oct 20197:00 amRNSPortfolio Update
1st Oct 20199:21 amRNSHolding(s) in Company
27th Sep 20194:49 pmRNSHolding(s) in Company
27th Sep 20193:47 pmRNSHolding(s) in Company
27th Sep 20193:46 pmRNSHolding(s) in Company
27th Sep 201912:46 pmRNSHolding(s) in Company
27th Sep 20197:00 amRNSHolding(s) in Company
26th Sep 20198:00 amRNSPDMR shareholdings
25th Sep 20193:16 pmRNSHolding(s) in Company
25th Sep 20193:12 pmRNSDirector Declaration
24th Sep 20197:00 amRNSResult of Placing under Placing Programme
20th Sep 20197:00 amRNSPlacing Update
18th Sep 20197:00 amRNSAnnouncement of Placing Price
10th Sep 20197:00 amRNSPlacing under Placing Programme
30th Aug 20197:00 amRNSNet Asset Value(s)
16th Aug 20197:00 amRNSPortfolio Update
6th Aug 20192:20 pmRNSPortfolio Update
4th Jul 20197:00 amRNSPortfolio Update
28th Jun 20196:31 pmRNSHalf-year Report
20th Jun 20197:00 amRNSCorporate Update
31st May 20197:00 amRNSNet Asset Value(s)
7th May 20193:55 pmRNSHolding(s) in Company
26th Apr 20193:36 pmRNSHolding(s) in Company
24th Apr 20191:10 pmRNSHolding(s) in Company
24th Apr 20191:08 pmRNSHolding(s) in Company
24th Apr 20191:06 pmRNSHolding(s) in Company
18th Apr 20194:52 pmRNSDirector/PDMR Shareholding
18th Apr 20191:43 pmRNSHolding(s) in Company
16th Apr 20197:00 amRNSResult of Placing under Placing Programme
15th Apr 20197:00 amRNSPlacing Update
12th Apr 20198:46 amRNSProposed Placing Price
12th Apr 20198:45 amRNSPortfolio Update
26th Mar 20197:00 amRNSPlacing under Placement Programme
5th Mar 20197:00 amRNSNAV Announcement and Portfolio Update
22nd Feb 20191:22 pmRNSStarling Bank awarded CIF Pool A grant
13th Feb 20197:00 amRNSPortfolio Update
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.